10x Genomics
258 hedge funds and large institutions have $5.03B invested in 10x Genomics in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 85 increasing their positions, 82 reducing their positions, and 48 closing their positions.
183% more call options, than puts
Call options by funds: $30.7M | Put options by funds: $10.9M
58% more capital invested
Capital invested by funds: $3.19B → $5.03B (+$1.84B)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
1.05% more ownership
Funds ownership: 91.59% → 92.63% (+1%)
4% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 82
4% less funds holding
Funds holding: 268 → 258 (-10)
17% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$75.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$74.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$49M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$47.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$46.2M |
| 2 |
Wolverine Trading
Chicago,
Illinois
|
-$34.2M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$33.4M |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$30.4M |
| 5 |
Man Group
London,
United Kingdom
|
-$25.4M |
TXG Hedge Fund Activity: Q1 2023 in Review
258 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2023, worth a combined $5.03B — up 58% from $3.19B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of TXG and 40 opened new positions — a net loss of 8 holders — while 82 trimmed existing stakes and 85 added.
The largest buyer was Brown Capital Management, adding an estimated $75.7M. The largest seller was Millennium Management, cutting an estimated $46.2M.
- 258 institutional investors held 10x Genomics (TXG) as of Q1 2023, down from 268 in Q4 2022.
- Funds reported $5.03B of 10x Genomics stock for Q1 2023, up 58% quarter-over-quarter.
- 40 funds opened new 10x Genomics positions in Q1 2023 and 48 closed out, a net change of -8 holders.
- The largest 10x Genomics buyer in Q1 2023 was Brown Capital Management, an estimated $75.7M added.
- The largest 10x Genomics seller in Q1 2023 was Millennium Management, an estimated $46.2M sold.
Based on aggregated 13F filings for Q1 2023.